comparemela.com

Chipscreen Newway News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

/PRNewswire/ Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewWay) announced that on January 5, 2024, the dosing of the first patient for a phase I.

Hong kongUnited statesSan franciscoChipscreen newway biosciencesChipscreen newwayHaimen jiangsuChipscreen biosciencesChipscreen biosciences united statesShenzhen chipscreen pharmaceuticals co ltdShanghai business centerBiocytogen pharmaceuticals beijing co ltdPrnewswire chengdu chipscreen newway biosciences co ltdShenzhen chipscreen biosciences co ltdSun yat sen university cancer centerChengdu chipscreen pharmaceuticals co ltdEucure beijing biopharma co ltd

Biocytogen s Subsidiary Eucure Biopharma and Chipscreen Biosciences Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ( Biocytogen , HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd.

United statesHong kongBaden wübergHaimen jiangsuChipscreen newway biosciencesChipscreen biosciencesYuelei shenEucure biopharmaChipscreen newwayXianping luEucure beijing biopharma co ltdDrug administrationBiocytogen pharmaceuticals beijing co ltdHead of the centerShenzhen chipscreen biosciences co ltdGreater china

vimarsana © 2020. All Rights Reserved.